Mbx Biosciences, Inc. · NASDAQ:MBX
Mbx Biosciences — Investor Presentation (August 2026)
26 slides from Mbx Biosciences's investor presentation, Aug 6, 2026
Slide 1: Pioneering Precision Peptides for Endocrine and Metabolic Diseases
Pioneering Precision Peptides for Endocrine and Metabolic Diseases August 2026 Corporate Presentation
Slide 2: Disclaimer
Disclaimer This presentation includes forward looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our product candidates, preclinical study and/or clinical trial timelines, including projected data announcements,
Slide 3: MBX: Catalyst-Rich Year
$418.6 million in cash expected to provide runway into 20291 Program Milestone Anticipated Timing Canvuparatide (MBX 2109) End-of-Phase 2 FDA Meeting Avail™ Phase 2 presentation and one-year OLE data Phase 3: Initiation Q3 2026 MBX 4291 (GLP-1/GIP) Phase 1: 12-week MAD results Q4 2026 MBX 5765 (amyc
Slide 4: Clinically Validated Precision Endocrine Peptide (PEP) Platform
Clinically Validated Precision Endocrine Peptide (PEP™) Platform Created by MBX and Scientific Co-Founder Richard DiMarchi, PhD INNOVATIVE PEPTIDE DESIGN With a goal to optimize: Multiple mechanisms of action within a single peptide Increased potency Enhanced physical properties, including stability
Slide 5: Canvuparatide: Once-Weekly PTH Replacement Therapy for Hypoparathyroidism
Canvuparatide Investigational Once-Weekly PTH Replacement Therapy for Hypoparathyroidism
Slide 6: Chronic Hypoparathyroidism Affects Thousands of Patients Worldwide
Chronic Hypoparathyroidism Affects Thousands of Patients Worldwide Source: 1Mannstadt et al, Nat Rev Dis Primers, 2017; Powers et al, JBMR., 2013; Vadiveloo et al, JBMR 2017; Cianferotti et al, Calcif Tissue Int, 2018; Swartling et al, J Clin Endocrinol Metab, 2022; Underbjerg et al, JBMR. 2013; Soi
Slide 7: Once-Weekly Canvuparatide Demonstrated Competitive Responder Rates in Phase 2 Avail Trial
Once-Weekly Canvuparatide Demonstrated Competitive Responder Rates in the Phase 2 Avail Trial and Open Label Extension Tx, treatment; Data sourced from (1)“PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism”, https://pmc.ncbi.nlm.ni
Slide 8: Pivotal Phase 3 Trial of Once-Weekly Canvuparatide
Pivotal Phase 3 Trial of Once-Weekly Canvuparatide QW: once weekly Phase 3 Trial Endpoints Treatment Period: 26 weeks 4- Week Fixed Dose Treatment Period 18-Week Dose Adjustment Period 3:1 N=160 600 μg Canvuparatide QW (n=120) QW Placebo (n=40) Titrate Canvuparatide Titrate Placebo Open-Label Extens
Slide 9: Once-Weekly Canvuparatide has the Potential to be the New Standard of Care
Once-Weekly Canvuparatide has the Potential to be the New Standard of Care for Patients with Chronic HP Source: MBX market research May 2026 First once-weekly PTH replacement therapy Restore normal serum calcium and phosphate Protect kidneys from long-term damage Restore bone turnover Free patients
Slide 10: Obesity Portfolio
Obesity Portfolio
Slide 11: Worldwide Obesity Prevalence
Worldwide Obesity Prevalence Obesity rates have doubled since 1990 25% of the World’s Population is projected to have obesity by 2035 390 million children and adolescents overweight 1 in 8 people worldwide are living with obesity 160 million children living with obesity 890 million adults living wit
Slide 12: High Discontinuation Rates with Currently Available Treatments
High Discontinuation Rates with Currently Available Treatments Underscore Need for Improved Tolerability Source: Market research data conducted by ClearView on behalf of MBX Proportion discontinued, % 100 80 60 40 20 0 0 1 2 Time since initiation, y Real World Discontinuation 65% (1-yr) 84% (2-yr) P
Slide 13: Obesity Opportunity: Once-Monthly Dosing with Improved Tolerability
Obesity Opportunity: Once-Monthly Dosing with Improved Tolerability MBX obesity candidates are designed using proprietary PEP platform for once-monthly dosing with the goal of more gradual, flattened and sustained exposure and improved tolerability Source for tirzepatide concentrations: CPT Pharmaco
Slide 14: MBX 4291: Engineered for Gradual Release, Long Exposure and Dual GLP-1/GIP Agonism
MBX 4291: Engineered for Gradual Release, Long Exposure and Dual GLP-1/GIP Agonism MBX scientific founder, Richard DiMarchi, PhD 14
Slide 15: MBX 4291 Ongoing Phase 1 Clinical Trial
SAD (Part A) MAD (Part B) MAD (Part C) Participants BMI > 30 Design N=40 N=24 N=60 5 Cohorts 3 Cohorts 2 Cohorts1 X X X Single dose (15 mg to 180 mg) 4 weekly doses followed by a single monthly dose 4 weekly doses followed by once monthly dosing for a total of 12 weeks MBX 4291 Ongoing Phase 1 Clini
Slide 16: MBX 4291 Preliminary SAD Data Demonstrates Dose-Proportional PK
MBX 4291 Phase 1 Preliminary SAD Data Demonstrates Dose-Proportional PK with Gradually Increasing and Sustained Concentrations of Active Peptide after a Single Dose Source: MBX 4291 Phase 1 trial, ongoing and blinded 120 mg cohort ongoing
Slide 17: MBX 4291 Preliminary PK from First MAD Cohort
MBX 4291 Preliminary PK from First MAD Cohort Indicates Gradual Accumulation and Sustained Concentrations of Active Peptide Source: MBX 4291 Phase 1 trial is ongoing and blinded *n = 6 through 28 days; n = 3 28 through 56 days (additional analysis pending) 180 mg SAD vs. 1st MAD Cohort 17 MBX 4291 P
Slide 18: MBX 4291 PK Supports Potential for True Once-Monthly Dosing
MBX 4291 PK Supports Potential for True Once-Monthly Dosing 1st Multiple Ascending Dose (Part B) Source for MET-0971i concentrations: estimated from graphics presented in Metsera, Inc. Form S-1, filed January 10, 2025. Source for MBX 4291: MBX 4291 Phase 1 trial, ongoing and blinded T1/2Cmax calcula
Slide 19: MBX 4291 First MAD Cohort: Competitive Weight Loss and Tolerability
Mean weight loss of 7% (range 0-16%) at 8 weeks (n=8, including 2 placebo) MBX 4291 First MAD Cohort: Competitive Weight Loss and Tolerability with Potential for True Once-Monthly Dosing 30 mg qw x4 + 120 mg single dose Safety and Tolerability Only 1/8 subjects experienced an event of diarrhea, naus
Slide 20: MBX 4291 Initial Phase 1 Data Summary
MBX 4291 Initial Phase 1 Data Summary MBX 4291 designed for once-monthly dosing with controlled, sustained concentrations and improved tolerability Data from the Phase 1 SAD show a PK profile supporting a self-titrating weekly induction regimen and potential for a true once-monthly regimen Prelimina
Slide 21: MBX 5765: Multi-Agonist Amycretin Prodrug Designed for Once-Monthly Dosing
GLP-1 GIP GCG DACRA (amylin + calcitonin) Potential to improve efficacy compared to CagriSema or semaglutide, alone or as mix Improved tolerability due to gradual, controlled release of active drug Potential for a more simplified development path compared to a mix of novel agonists MBX 5765: Multi-A
Slide 22: MBX 5765's Flat PK Profile Supports Potential Long Time Action
22 we MBX 5765’s Flat PK Profile Supports Potential Long Time Action and Minimized Concentration Variability MBX 5765 single dose in non-human primates Semaglutide data linearly scaled from a 10 nmol/kg dose; Novo amycretin data linearly scaled from a 30 nmol/kg dose. Data shown in this figure repre
Slide 23: MBX 5765: Observations and Body Weight Loss
MBX 5765: Observations and Body Weight Loss Effects on body weight persisted the entire 3-week monitoring interval from a single dose whereas side effects consistent with incretins/DACRAs (dehydration, lethargy) recovered within the first week Expected PD effects seen for a single 50 nmol/kg dose co
Slide 24: Obesity Pipeline Designed to Address Broad Range of Obesity Patient Needs
Obesity Pipeline Designed to Address Broad Range of Obesity Patient Needs MBX Obesity Portfolio MBX 4291 GLP-1/GIP Dual Agonist MBX 5765 Amycretin MBX 6180 GGG Triple agonist 1 2 3 MBX is developing a robust obesity portfolio with potential to drive strong optionality across patient segments 24
Slide 25: MBX: Catalyst-Rich Year
$418.6 million in cash expected to provide runway into 20291 Program Milestone Anticipated Timing Canvuparatide (MBX 2109) End-of-Phase 2 FDA Meeting Avail™ Phase 2 presentation and one-year OLE data Phase 3: Initiation Q3 2026 MBX 4291 (GLP-1/GIP) Phase 1: 12-week MAD results Q4 2026 MBX 5765 (amyc
Slide 26: Our Mission
Transforming the Lives of People Impacted by Endocrine and Metabolic Diseases through Precision Peptides Our Mission
MBX Biosciences — Investor Presentation (August 2026) on 6ix